Ovid Therapeutics is a clinical stage biopharmaceutical company committed to transforming the lives of patients with rare and orphan diseases of the brain. Ovid’s most advanced investigational medicine, OV101 (gaboxadol), is currently in clinical development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 (soticlestat) in…
16 Search Results for “covid”
Ovid Therapeutics is a clinical stage biopharmaceutical company committed to transforming the lives of patients with rare and orphan diseases of the brain. Ovid’s most advanced investigational medicine, OV101 (gaboxadol), is currently in clinical development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 (soticlestat) in collaboration…
Ovid Therapeutics is a clinical stage biopharmaceutical company committed to transforming the lives of patients with rare and orphan diseases of the brain. The Companys most clinically-advanced product candidate, OV101, is a first-in-class ?-selective GABAA receptor agonist. OV101 is currently Phase III ready in Angelman syndrome (AS). Ovid announced positive topline Phase II…
Ovid Therapeutics is a clinical stage biopharmaceutical company committed to transforming the lives of patients with rare and orphan diseases of the brain. Ovid’s most advanced investigational medicine, OV101 (gaboxadol), is currently in clinical development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 (soticlestat) in…
Ovid Therapeutics is a clinical stage biopharmaceutical company committed to transforming the lives of patients with rare and orphan diseases of the brain. Ovid’s most advanced investigational medicine, OV101 (gaboxadol), is currently in clinical development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 (soticlestat) in…
Ovid Therapeutics Inc. is a clinical stage biopharmaceutical company committed to transforming the lives of patients with rare and orphan diseases of the brain. The Company’s most clinically-advanced product candidate, OV101, is a first-in-class δ-selective GABAA receptor agonist. Ovid is also developing OV935 (soticlestat) in collaboration with Takeda Pharmaceutical Company for the potential treatment…
CTI BioPharma (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI concentrates its efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, CTI focuses on developing and commercializing Pacritinib, its product candidate…
Novavax, Inc. (NVAX) (“Novavax”) is a biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax’s proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticle vaccines designed to address urgent global health needs. Novavax…
Novavax, Inc. (NVAX) (“Novavax”) is a biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax’s proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticle vaccines designed to address urgent global health needs. Novavax…
Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company dedicated to the development and commercialization of novel vaccines. Dynavax’s sole marketed product, HEPLISAV-B, was approved in November 2017 and launched in February 2018 for the prevention of infection caused by all known subtypes of Hepatitis B virus in adults age 18 years or older. Dynavax is…
Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company launched its first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], in February 2018, following U.S. FDA approval for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also developing CpG 1018 as an advanced vaccine…
Icosavax (the “Company”) is a biotechnology company developing virus-like particle (VLP) vaccine candidates against respiratory syncytial virus (RSV), human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The Company’s VLP platform technology is designed to enable a multivalent, particle-based display of complex viral antigens, which could induce broad, robust and durable protection against the specific targeted virus. Icosavax’s lead vaccine candidate, IVX-A12, is a…
Load More